Ultragenyx Pharmaceutical Shares Rise 14% Following Interim

By Denny Jacob Ultragenyx Pharmaceutical shares rose 14% to $38.18 following interim data from ongoing studies. The stock is down 18% on the year so far. The...

Related Keywords

Denny Jacob , Emil Kakkis , , Osteogenesis Imperfecta , Chief Executive Emil , Article Normal , Pharmaceuticals , Healthcare Life Sciences , Financial Performance , Corporate Industrial News , Equity Markets , Commodity Financial Market News , Content Types , Factiva Filters , C Amp Ampe Exclusion Filter , C Amp Ampe Industry News Filter , Synd , Ultragenyx Pharmaceutical , Rare , Corporate , Industrial News , Commodity , Financial Market News , Healthcare , Life Sciences ,